Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339644 | 0.88 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5965360 | 0.85 | GAA (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL338881 | 0.77 | TSHR (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL339885 | 0.75 | — | — | |
| SCHEMBL6517025 | 0.75 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2555430 | 0.74 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL354702 | 0.74 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11577077 | 0.72 | POLB (0.60) | ALDH1A1TSHRHSD17B10MEN1KMT2A | |
| SCHEMBL236360 | 0.69 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5547692 | 0.69 | CA12 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843590-A | 3-amino-4- (piperazin-1-yl) benzamide derivative, pharmaceutical composition containing same, and preparation method and application thereof | 中国药科大学 | 2024-04-09 | — | — | CN | claimed |
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | claimed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | claimed |
| EP-1310510-B1 | Topologically segregated, encoded solid phase libraries | AVENTIS PHARMA INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1625158-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | claimed |
| US-20050119181-A1 | Hydrophobically-modified protein compositions and methods | BIOGEN IDEC INC. (US) | 2005-06-02 | — | — | US | claimed |
| EP-1036092-B1 | Hydrophobically-modified hedgehog protein compositions and methods | BIOGEN INC (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2004099246-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| EP-0813544-B1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH INC (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0323740-A2 | Linear analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1989-07-12 | — | — | EP | claimed |
| WO-1989005654-A1 | LINEAR ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-06-29 | — | — | WO | claimed |
| US-4804650-A | DIURETICS, VASODILATORS | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1989-02-14 | — | — | US | claimed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | claimed |
| EP-0223143-A2 | Analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1987002674-A1 | ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1987-05-07 | — | — | WO | claimed |
| US-4402981-A | ANTIULCER AGENT | KALI-CHEMIE PHARMA, GMBH (DE) | 1983-09-06 | — | — | US | claimed |
| US-4094976-A | ANTICOCCIDIAL CYCLICAMINO ETHANOLS AND ESTERS THEREOF | MERCK & CO., INC. (US) | 1978-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244054-A1 | Peptides for use in treating obesity | NPY4R, GLP1R, NPY1R | GRIN2D 3889/4885GRIN3B 1838/4885GRIN1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.